What's Going On With Eli Lilly Shares Monday?

Zinger Key Points
  • Eli Lilly announced detailed results from the SURMOUNT-OSA phase 3 clinical trials on Friday.
  • Cantor Fitzgerald, BofA Securities and Jefferies released positive analyst updates on Monday.

Eli Lilly and Co LLY shares are moving higher Monday following the release of positive Phase 3 trial results for its weight loss drug, tirzepatide, marketed as Zepbound.

What Happened: The trials, known as SURMOUNT-OSA, demonstrated significant improvements in moderate-to-severe obstructive sleep apnea (OSA) patients with obesity, Eli Lilly said late Friday.

Tirzepatide achieved a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI) and showed disease resolution in over 40% of participants, defined as having achieved fewer than five events per hour or a reduced Epworth Sleepiness Scale (ESS) score.

The weight loss outcomes were notable, with participants experiencing average reductions of 18.1% in OSA 1 and 20.1% in OSA 2. These promising results have laid the groundwork for potential label expansion, with Eli Lilly submitting tirzepatide for FDA approval for treating moderate-to-severe OSA and obesity, anticipated by year-end.

Analysts have responded positively on Monday. Cantor Fitzgerald reiterated an Overweight rating and price target of $885 and BofA Securities maintained a Buy rating with a $1,000 price target. Jefferies also maintained a Buy rating and raised its price target from $994 to $1,015.

It’s also worth noting that Eli Lilly’s board declared a third-quarter dividend of $1.30 per share on Monday. The quarterly dividend will be payable on Sept. 10 to shareholders of record as of Aug. 15.

LLY Price Action: Eli Lilly shares closed Monday up 0.76% at $890.11, according to Benzinga Pro.

See Also: Why ResMed Shares Are Trading Lower Monday

Photo by rafapress on Shutterstock.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!